カテゴリ： GlobalData, オランダ, 企業調査

Qiagen NV (QIA)-医療機器分野：企業M&A・提携分析

◆英語タイトル：Qiagen NV (QIA) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA8010984
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月21日
◆ページ数：165
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：オランダ
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Qiagen NV (Qiagen) is a provider of molecular testing solutions. Its solutions include sample and assay technologies, bioinformatics and automation systems. Qiagen’s sample technologies help isolate and process DNA, RNA and proteins from samples such as blood and tissue. The company’s product portfolio includes consumable products, automated solutions for sample collection, and open and target specific assays. Qiagen also supplies diagnostic test kits and assays for human and veterinary molecular diagnostics. The company serves animal pathogens and genotyping, cancer research, and environmental water testing, among other sectors. Qiagen offers solutions to pharmaceutical and biotechnology companies, and research institutions. It has operations across the Americas; Europe, the Middle East, Africa, and Asia Pacific. Qiagen is headquartered in Venlo, the Netherlands.

Qiagen NV (QIA) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Qiagen NV, Medical Equipment, Deals By Year, 2011 to YTD 2017 9
Qiagen NV, Medical Equipment Deals By Type, 2011 to YTD 2017 10
Qiagen NV, Medical Equipment, Deals By Region, 2011 to YTD 2017 11
Qiagen NV, Medical Equipment, Deals By Market, 2011 to YTD 2017 12
Qiagen NV, Medical Equipment, Deals Summary, 2011 to YTD 2017 13
Qiagen NV, Medical Equipment, Deal Details 18
Asset Purchase 18
QIAGEN Acquires Circulating Tumor Cell Technology from AdnaGen 18
Venture Financing 19
Exosome Diagnostics Raises USD60 Million in Series B Financing Round 19
Protagen Raises USD12.5 Million in Venture Financing 21
Curetis Raises USD18 Million in Extended Series B Venture Financing 22
Exosome Diagnostics Raises US$27 Million In Series B Financing Round 24
Drug Response Dx Raises Funds Through First Round Of Venture Financing 26
Xagenic Raises US$10 Million In Series A Venture Financing 27
Partnerships 28
Qiagen Enters into Licensing Agreement with Johns Hopkins University 28
QIAGEN Enters into Licensing Agreement with Johns Hopkins University 29
Qiagen Enters into Licensing Agreement with MDxHealth 30
Qiagen Enters Into Licensing Agreement With CeMM For Calreticulin Biomarker 31
Qiagen Enters Into Option For Licensing Agreement With Columbia University For FGFR-TACC Fusion Genes 32
Qiagen Enters Into Option For Licensing Agreement With BC Cancer For EZH2 Y641 Mutation Biomarker 33
IntelligentMDx Enters Into Licensing Agreement with Qiagen To Develop Molecular Tests 34
Qiagen Enters Into Licensing Agreement With Drug Response Dx For Rheumatoid Arthritis Biomarkers 35
Qiagen Enters Into Licensing Agreement With Insight Genetics For Lung Cancer Biomarkers 36
Qiagen Enters Into Licensing Agreement With Inserm Transfert For Colorectal Cancer Biomarker 37
Ingenuity Systems Enters Into Licensing Agreement With LabCorp For Clinical Content And Applications 38
QIAGEN Enters Into Licensing Agreement With Personal Genome Diagnostics 39
Orion Genomics Enters Into Licensing Agreement With QIAGEN 40
Mayo Medical Labs Enters Into Licensing Agreement With Qiagen 41
Epigenomics Announces Option Licensing Agreement With QIAGEN 42
Epigenomics Enters Into Research Licensing Agreement With QIAGEN 43
Biomillenia Enters into Agreement with Qiagen 44
Qiagen and Centogene Enter into Co-Marketing Agreement 45
ANGLE Enters into Co-Marketing Agreement with Qiagen 46
DiaSorin Enters into Agreement with QIAGEN 47
Qiagen Forms Joint Venture with Maccura Biotech 48
Singulex Enters into Agreement with Qiagen 49
Sophia Genetics Enters into Agreement with Qiagen 50
Qiagen Enters into Agreement with Genohm 51
CareDx to Partner with Qiagen 52
Qiagen Enters into Partnership with Therawis Diagnostics 53
CosmosID Enters into Agreement with Qiagen 54
NanoString Technologies Enters into Co-Development Agreement with HalioDx 55
Qiagen Enters into Agreement with 10X Genomics 56
Qiagen Enters into Co-Development Agreement with Array BioPharma 57
Qiagen Forms Joint Venture with Biotype Diagnostics 58
Qiagen Enters into Agreement with Hitachi High-Technologies 59
Qiagen Enters into Agreement with GATC Biotech 60
Tokai Pharma Expands Agreement with Qiagen 61
Qiagen Enters into Distribution Agreement with Altona Diagnostics for RealStar Ebolavirus RT-PCR Kit 1.0 62
Protagen Enters into Agreement with Qiagen to Develop Novel Protein-Based Companion Diagnostics 63
Qiagen Enters into Co-Development Agreement with Novartis 64
Qiagen Enters into Co-Development Agreement with Astellas Pharma 65
AstraZeneca Enters into Co-Development Agreement with Qiagen 66
Qiagen Enters into Co-Development Agreement with Eli Lilly for Companion Diagnostic Test 67
Maverix Biomics Extends Co-Marketing Agreement With Qiagen 68
Qiagen And Exosome Diagnostics Enter Into Agreement To Develop Diagnostics For Cancer Biomarkers 69
Qiagen And Eli Lilly Enter Into Co-Development Agreement For Companion Diagnostic Test 70
Maverix Biomics Enters Into Co-Marketing Agreement With Qiagen 71
Clovis Oncology Enters Into Co-Development Agreement With Qiagen 72
Exosome Diagnostics And Qiagen Enter Into Agreement To Develop Line Of Biofluid Nucleic Acid Kits 74
Qiagen Forms Joint Venture With BioBay To Establish Translational Medicine Center 75
Ingenuity Systems Enters Into Co-Promotion Agreement With Affymetrix For Research Tools 77
PrimeraDx Enters Into Co-Development Agreement With Quest Diagnostics 78
Ingenuity Systems Enters Into Agreement With GeneInsight To Deliver Integrated Workflow Solution To Clinical Labs 79
Qiagen Enters Into Co-Development Agreement With Eli Lilly 80
Qiagen Enters Into Agreement With Clarient To Offer therascreen KRAS RGQ PCR Kit 81
Qiagen Enters Into Agreement With Bayer HealthCare To Develop Diagnostics Test In Oncology 82
Ingenuity Systems Enters Into Co-Development Agreement With Life Technologies For Diagnostic Solutions 83
Qiagen Enters Into Co-Marketing Agreement With Lepu Medical 84
PrimeraDx Enters Into Co-Development Agreement With Eli Lilly 85
Cardinal Health Enters Into Distribution Agreement With Qiagen For Molecular Diagnostic Products 86
Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For LongRange PCR Kit 87
QIAGEN Enters Into Co-Development Agreement With Insight Genetics 88
QIAGEN Enters Into Co-Development Agreement With Max Planck Institute 89
QIAGEN Enters Into Co-Development Agreement With Eli Lilly 90
Qiagen Enters Into Co-Development Agreement With Pfizer 91
IPSOGEN Enters Into Distribution Agreement With Sysmex 92
Olerup Enters Into Co-Marketing Agreement With QIAGEN 93
EyeSense Enters Into An Agreement With QIAGEN 94
Inserm Transfert Enters into Licensing Agreement with HalioDx 95
Transgenomic Expands Licensing Agreement with Exiqon 96
Qiagen Enters into Licensing Agreement with University of Tokyo for SF3B1 97
Equity Offering 98
Exiqon Completes Private Placement Of Shares For US$2.6 Million 98
Debt Offering 99
Qiagen Raises USD400 Million in Private Placement of Notes 99
Exiqon Raises USD5.8 Million in Private Placement of 9.25% Note 100
Qiagen Completes Public Offering Of Senior Notes Due 2019 For US$430 Million 101
Qiagen Completes Public Offering Of Senior Notes Due 2021 For US$300 Million 102
Exiqon Completes Private Placement Of Bonds For US$3 Million 103
Asset Transactions 104
Diatherix Labs Acquires Tem-PCR Patent From Qiagen 104
Acquisition 105
Qiagen Acquires OmicSoft 105
Qiagen Acquires Exiqon for up to USD102.4 Million 106
Qiagen Acquires MO BIO Labs 108
Qiagen Acquires PrimeraDx, Molecular Diagnostic Company 109
Qiagen Acquires CLC bio, Bioinformatics Software Company 110
Qiagen Acquires AmniSure International, Manufacturer Of Non Invasive Test Solutions 111
Qiagen Completes Acquisition Of Additional 26.7% Stake In Ipsogen For US$30 Million 112
Qiagen Completes Acquisition Of Cellestis 114
Qiagen NV – Key Competitors 116
Qiagen NV – Key Employees 117
Qiagen NV – Locations And Subsidiaries 118
Head Office 118
Other Locations & Subsidiaries 118
Joint Venture 121
Recent Developments 122
Financial Announcements 122
Jul 27, 2017: QIAGEN Reports Results for Second Quarter and First Half of 2017 122
May 02, 2017: QIAGEN reports results for first quarter 2017 125
Feb 01, 2017: QIAGEN Reports Results for Fourth Quarter and Full-year 2016 127
Nov 02, 2016: QIAGEN Reports Results for Third Quarter and First Nine Months of 2016 131
Jul 28, 2016: QIAGEN Reports Results for Second Quarter of 2016; Increased Commitment to Return $300 Million of Capital to Shareholders by End-2017 134
Apr 27, 2016: QIAGEN Reports Results for First Quarter of 2016 137
Feb 02, 2016: QIAGEN Reports Results for Fourth Quarter and Full-Year 2015 140
Jan 10, 2016: QIAGEN Announces Preliminary Results for Full-Year 2015 and Provides 2016 Outlook 144
Corporate Communications 145
Jul 04, 2016: Exiqon – Nomination of candidates for the supervisory board 145
Government and Public Interest 146
Mar 30, 2017: QIAGEN joins CANCER-ID consortium for liquid biopsy workflows 146
Product News 147
Nov 15, 2017: QIAGEN advances precision medicine by automating guidelines on cancer variants in industry-leading QIAGEN Clinical Insight software 147
Apr 03, 2017: QIAGEN’s GeneReader NGS System gains further validation in oncology research applications with new independent performance review data 148
Nov 22, 2016: QIAGEN and CosmosID Launch New Plugin for Metagenomics Analysis 149
Oct 20, 2016: QIAGEN launches QIAscout for single-cell isolation 150
Oct 10, 2016: QIAGEN launches high-throughput solutions for human ID databases 151
Jul 27, 2016: QIAGEN launches “Digital NGS” solutions with unique Molecular Index Technology to reliably detect all genetic variation 152
May 19, 2016: QIAGEN Bioinformatics Continues to Set the Standard With Hereditary Disease Solution 153
Apr 14, 2016: QIAGEN launches streamlined bioinformatics for RNA sequencing of liquid biopsies 154
02/15/2016: Multi-center Study Confirms Value of QIAGEN’s QuantiFERON-TB Gold Plus 155
Feb 11, 2016: QIAGEN Launches Targeted RNA Panels for Next-generation Sequencing 156
01/26/2016: QIAGEN to Supply QuantiFERON-TB Tests to Ease Tuberculin Shortage 157
Other Significant Developments 158
Jan 30, 2017: QIAGEN Hereditary and Rare Disease Solution Chosen by Genomics England 158
Nov 09, 2016: QIAGEN’s GeneReader NGS System streamlines data management for labs 159
Nov 02, 2016: QIAGEN launches restructuring initiatives, revises outlook for 2016 earnings and provides initial net sales and adjusted earnings guidance for 2017 160
Sep 29, 2016: QIAGEN and ICMP to develop first NGS workflow for identification of missing persons 161
Jun 21, 2016: QIAGEN Joins Consortium to Map Microbial Genomes in 54 Cities 162
Jun 01, 2016: Horizon Discovery Group’s Molecular Reference Standards integrated into QIAGEN GeneReader NGS System 163
Feb 02, 2016: New agreements underscore QIAGEN’s leadership in bioinformatics 164
Appendix 165
Methodology 165
About GlobalData 165
Contact Us 165
Disclaimer 165

List of Tables
Qiagen NV, Medical Equipment, Key Facts, 2016 2
Qiagen NV, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Qiagen NV, Medical Equipment, Deals By Year, 2011 to YTD 2017 9
Qiagen NV, Medical Equipment Deals By Type, 2011 to YTD 2017 10
Qiagen NV, Medical Equipment, Deals By Region, 2011 to YTD 2017 11
Qiagen NV, Deals By Market, 2011 to YTD 2017 12
Qiagen NV, Medical Equipment, Deals Summary, 2011 to YTD 2017 13
QIAGEN Acquires Circulating Tumor Cell Technology from AdnaGen 18
Exosome Diagnostics Raises USD60 Million in Series B Financing Round 19
Protagen Raises USD12.5 Million in Venture Financing 21
Curetis Raises USD18 Million in Extended Series B Venture Financing 22
Exosome Diagnostics Raises US$27 Million In Series B Financing Round 24
Drug Response Dx Raises Funds Through First Round Of Venture Financing 26
Xagenic Raises US$10 Million In Series A Venture Financing 27
Qiagen Enters into Licensing Agreement with Johns Hopkins University 28
QIAGEN Enters into Licensing Agreement with Johns Hopkins University 29
Qiagen Enters into Licensing Agreement with MDxHealth 30
Qiagen Enters Into Licensing Agreement With CeMM For Calreticulin Biomarker 31
Qiagen Enters Into Option For Licensing Agreement With Columbia University For FGFR-TACC Fusion Genes 32
Qiagen Enters Into Option For Licensing Agreement With BC Cancer For EZH2 Y641 Mutation Biomarker 33
IntelligentMDx Enters Into Licensing Agreement with Qiagen To Develop Molecular Tests 34
Qiagen Enters Into Licensing Agreement With Drug Response Dx For Rheumatoid Arthritis Biomarkers 35
Qiagen Enters Into Licensing Agreement With Insight Genetics For Lung Cancer Biomarkers 36
Qiagen Enters Into Licensing Agreement With Inserm Transfert For Colorectal Cancer Biomarker 37
Ingenuity Systems Enters Into Licensing Agreement With LabCorp For Clinical Content And Applications 38
QIAGEN Enters Into Licensing Agreement With Personal Genome Diagnostics 39
Orion Genomics Enters Into Licensing Agreement With QIAGEN 40
Mayo Medical Labs Enters Into Licensing Agreement With Qiagen 41
Epigenomics Announces Option Licensing Agreement With QIAGEN 42
Epigenomics Enters Into Research Licensing Agreement With QIAGEN 43
Biomillenia Enters into Agreement with Qiagen 44
Qiagen and Centogene Enter into Co-Marketing Agreement 45
ANGLE Enters into Co-Marketing Agreement with Qiagen 46
DiaSorin Enters into Agreement with QIAGEN 47
Qiagen Forms Joint Venture with Maccura Biotech 48
Singulex Enters into Agreement with Qiagen 49
Sophia Genetics Enters into Agreement with Qiagen 50
Qiagen Enters into Agreement with Genohm 51
CareDx to Partner with Qiagen 52
Qiagen Enters into Partnership with Therawis Diagnostics 53
CosmosID Enters into Agreement with Qiagen 54
NanoString Technologies Enters into Co-Development Agreement with HalioDx 55
Qiagen Enters into Agreement with 10X Genomics 56
Qiagen Enters into Co-Development Agreement with Array BioPharma 57
Qiagen Forms Joint Venture with Biotype Diagnostics 58
Qiagen Enters into Agreement with Hitachi High-Technologies 59
Qiagen Enters into Agreement with GATC Biotech 60
Tokai Pharma Expands Agreement with Qiagen 61
Qiagen Enters into Distribution Agreement with Altona Diagnostics for RealStar Ebolavirus RT-PCR Kit 1.0 62
Protagen Enters into Agreement with Qiagen to Develop Novel Protein-Based Companion Diagnostics 63
Qiagen Enters into Co-Development Agreement with Novartis 64
Qiagen Enters into Co-Development Agreement with Astellas Pharma 65
AstraZeneca Enters into Co-Development Agreement with Qiagen 66
Qiagen Enters into Co-Development Agreement with Eli Lilly for Companion Diagnostic Test 67
Maverix Biomics Extends Co-Marketing Agreement With Qiagen 68
Qiagen And Exosome Diagnostics Enter Into Agreement To Develop Diagnostics For Cancer Biomarkers 69
Qiagen And Eli Lilly Enter Into Co-Development Agreement For Companion Diagnostic Test 70
Maverix Biomics Enters Into Co-Marketing Agreement With Qiagen 71
Clovis Oncology Enters Into Co-Development Agreement With Qiagen 72
Exosome Diagnostics And Qiagen Enter Into Agreement To Develop Line Of Biofluid Nucleic Acid Kits 74
Qiagen Forms Joint Venture With BioBay To Establish Translational Medicine Center 75
Ingenuity Systems Enters Into Co-Promotion Agreement With Affymetrix For Research Tools 77
PrimeraDx Enters Into Co-Development Agreement With Quest Diagnostics 78
Ingenuity Systems Enters Into Agreement With GeneInsight To Deliver Integrated Workflow Solution To Clinical Labs 79
Qiagen Enters Into Co-Development Agreement With Eli Lilly 80
Qiagen Enters Into Agreement With Clarient To Offer therascreen KRAS RGQ PCR Kit 81
Qiagen Enters Into Agreement With Bayer HealthCare To Develop Diagnostics Test In Oncology 82
Ingenuity Systems Enters Into Co-Development Agreement With Life Technologies For Diagnostic Solutions 83
Qiagen Enters Into Co-Marketing Agreement With Lepu Medical 84
PrimeraDx Enters Into Co-Development Agreement With Eli Lilly 85
Cardinal Health Enters Into Distribution Agreement With Qiagen For Molecular Diagnostic Products 86
Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For LongRange PCR Kit 87
QIAGEN Enters Into Co-Development Agreement With Insight Genetics 88
QIAGEN Enters Into Co-Development Agreement With Max Planck Institute 89
QIAGEN Enters Into Co-Development Agreement With Eli Lilly 90
Qiagen Enters Into Co-Development Agreement With Pfizer 91
IPSOGEN Enters Into Distribution Agreement With Sysmex 92
Olerup Enters Into Co-Marketing Agreement With QIAGEN 93
EyeSense Enters Into An Agreement With QIAGEN 94
Inserm Transfert Enters into Licensing Agreement with HalioDx 95
Transgenomic Expands Licensing Agreement with Exiqon 96
Qiagen Enters into Licensing Agreement with University of Tokyo for SF3B1 97
Exiqon Completes Private Placement Of Shares For US$2.6 Million 98
Qiagen Raises USD400 Million in Private Placement of Notes 99
Exiqon Raises USD5.8 Million in Private Placement of 9.25% Note 100
Qiagen Completes Public Offering Of Senior Notes Due 2019 For US$430 Million 101
Qiagen Completes Public Offering Of Senior Notes Due 2021 For US$300 Million 102
Exiqon Completes Private Placement Of Bonds For US$3 Million 103
Diatherix Labs Acquires Tem-PCR Patent From Qiagen 104
Qiagen Acquires OmicSoft 105
Qiagen Acquires Exiqon for up to USD102.4 Million 106
Qiagen Acquires MO BIO Labs 108
Qiagen Acquires PrimeraDx, Molecular Diagnostic Company 109
Qiagen Acquires CLC bio, Bioinformatics Software Company 110
Qiagen Acquires AmniSure International, Manufacturer Of Non Invasive Test Solutions 111
Qiagen Completes Acquisition Of Additional 26.7% Stake In Ipsogen For US$30 Million 112
Qiagen Completes Acquisition Of Cellestis 114
Qiagen NV, Key Competitors 116
Qiagen NV, Key Employees 117
Qiagen NV, Other Locations 118
Qiagen NV, Subsidiaries 118
Qiagen NV, Joint Venture 121

★海外企業調査レポート[Qiagen NV (QIA)-医療機器分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Transat A.T. Inc：企業の戦略・SWOT・財務情報
    Transat A.T. Inc - Strategy, SWOT and Corporate Finance Report Summary Transat A.T. Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Bankers Insurance Group：企業の戦略・SWOT・財務分析
    Bankers Insurance Group - Strategy, SWOT and Corporate Finance Report Summary Bankers Insurance Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • The Royal Bank Of Scotland Group Plc
    The Royal Bank Of Scotland Group Plc - Strategy, SWOT and Corporate Finance Report Summary The Royal Bank Of Scotland Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Cymbet Corp：電力：M&Aディール及び事業提携情報
    Summary Cymbet Corp (Cymbet) is a clean technology company that offers energy storage solutions for microelectronic systems. The company’s products include EnerChip, EnerChip solid state batteries, EnerChip bare die, EnerChip RTC and evaluation kits. Its devices offers new concept in energy storage …
  • Mylan N.V.：企業の戦略・SWOT・財務分析
    Mylan N.V. - Strategy, SWOT and Corporate Finance Report Summary Mylan N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Hamon Research-Cottrell Inc：企業の戦略的SWOT分析
    Hamon Research-Cottrell Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Leonardo DRS Inc：企業の戦略的SWOT分析
    Leonardo DRS Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Hovnanian Enterprises, Inc.：企業の戦略・SWOT・財務情報
    Hovnanian Enterprises, Inc. - Strategy, SWOT and Corporate Finance Report Summary Hovnanian Enterprises, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Cognoptix Inc：医療機器：M&Aディール及び事業提携情報
    Summary Cognoptix Inc (Cognoptix), formerly Neuroptix Corp is a privately held medical technology company that develops and offers eye-scanning test for the early detection and diagnosis of Alzheimer’s disease. The company develops technology, which is used to detect the presence of Alzheimer’s rela …
  • Curtiss-Wright Corp (CW)：企業の財務・戦略的SWOT分析
    Curtiss-Wright Corp (CW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Avisa Pharma Inc-医療機器分野：企業M&A・提携分析
    Summary Avisa Pharma Inc (Avisa Pharma) is a medical device company that develops breath tests system for the diagnosis of pulmonary infections. The company’s product include avisa breath test kit, which is designed to detect respiratory bacterial infections in the lung and other metabolic diseases; …
  • HLS Therapeutics Inc (HLS)：製薬・医療：M&Aディール及び事業提携情報
    Summary HLS Therapeutics Inc (HLS Therapeutics) is a pharmaceutical company that offers central nervous system and cardiovascular therapeutic products. The company's product includes clozaril, absorica, vascepa and trinomial. Its clozapine is a pharmaceutical product used in the treatment of schizop …
  • Taageer Finance Company SAOG (TFCI)：企業の財務・戦略的SWOT分析
    Taageer Finance Company SAOG (TFCI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • F. Hoffmann-La Roche Ltd (ROG)：医療機器：M&Aディール及び事業提携情報
    Summary F. Hoffmann-La Roche Ltd (Roche) is a biotechnology company, which develops drugs and diagnostics that improve the standard of care in major disease areas. It provides pharmaceuticals in cancer, neuroscience, infection, immunology, ophthalmology, cardiovascular and metabolism, hematology, ne …
  • Bonnier AB：企業の戦略的SWOT分析
    Bonnier AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Interra Resources Ltd (5GI)：企業の財務・戦略的SWOT分析
    Summary Interra Resources Ltd (Interra) is an oil and gas company that explores and produces petroleum products. The company’s activities include field development and exploration, and petroleum products production and distribution services. Its production, development and exploration assets compris …
  • Shanghai Kehua Bio-engineering Co Ltd (002022)：企業の財務・戦略的SWOT分析
    Shanghai Kehua Bio-engineering Co Ltd (002022) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • SK Bioland Co Ltd：企業の戦略・SWOT・財務情報
    SK Bioland Co Ltd - Strategy, SWOT and Corporate Finance Report Summary SK Bioland Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Australian Postal Corporation：企業の戦略的SWOT分析
    Australian Postal Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Verastem Inc (VSTM)：製薬・医療：M&Aディール及び事業提携情報
    Summary Verastem Inc (Verastem) is a clinical-stage biopharmaceutical company with focus on the discovery, development and commercialization of drugs to treat cancer. The company’s lead product candidates include duvelisib, defactinib (VS-6063), FAK inhibitor (VS-4718) and PI3K/mTOR inhibitor (VS-55 …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆